MONTREAL, Feb. 22,
2022 /CNW Telbec/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of natural health products, is pleased to
announce that Jacqueline Khayat has
been appointed to the Board of Directors of the Company.
"As previously announced, we are executing the first phase of
our US expansion and we are very excited to have Ms. Khayat join
the board as we move into the next phase of our plan. Her
experience launching brands in the US will be a great asset to the
team" said Carlos Ponce, CEO of
Lumiera Health. "Ms. Khayat brings more than 20 years of
combined experience in sales, business development, strategy, and
M&A in the health & wellness sector."
Ms. Khayat's past experiences includes leadership positions at
Neptune Wellness Solutions where she led the development and launch
of several of the company's consumer product brands in USA and
other markets. Throughout her career, Ms. Khayat has also held
several key positions with global life science companies and has
experience leading sales teams, generating new business
opportunities, and M&A. In addition, Ms. Khayat has been
involved in several start-up companies as an investor and advisor.
She is also a Board Member of Caisse Populaire St-Martin de
Laval and a member of Anges
Quebec.
Ms. Khayat holds a bachelor's degree in Science with a Nutrition
major from the Faculty of Medicine of Montreal
University. She also holds a Graduate Degree in Management
from HEC Montreal and an Executive MBA from the John Molson School
of Business.
The Company's Board has granted an incentive stock options to
Mrs. Khayat, entitling the purchase of an aggregate 300,000 common
shares at a per share price of $0.05
for a period of 10 years.
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also commercializing a unique
topical product line acting on the endocannabinoid system, without
the use of cannabis, that provides an innovative solution for
chronic pain and inflammation. A pioneer in the natural health
innovation space, the Lumiera brand is rooted in the core values of
science, nature and compassion. Our goal is to make people's
lives better by developing natural health and wellness products
that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
Related Links: www.lumiera.ca
SOURCE Lumiera Health Inc.